[an error occurred while processing this directive]|[an error occurred while processing this directive]
初诊 ⅣB期胸段食管鳞癌综合放疗长期生存获益研究
王雪锋1,2, 曹峰1, 景绍武1, 王佳宁1, 史鸿云2, 王军1
1河北医科大学第四医院放疗科,石家庄 050011; 2河北大学附属医院放疗科,保定 071000
Radiotherapy is beneficial for long-term survival of patients with stage ⅣB thoracic esophageal squamous cell carcinoma at initial diagnosis
Wang Xuefeng1,2, Cao Feng1, Jing Shaowu1, Wang Jianing1, Shi Hongyun2, Wang Jun1
1Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China; 2Department of Radiation Oncology, Affiliated Hospital of Hebei Medical University, Baoding 071000, China
Abstract：Objective To investigate the value of radiotherapy in patients with stage ⅣB thoracic esophageal squamous cell carcinoma (ESCC) at initial diagnosis. Methods A total of 199 patients with stage ⅣB thoracic ESCC at initial diagnosis (according to UICC/AJCC Eighth Edition Esophageal and Esophagogastric Junction Cancer TNM Staging) who were treated in the Fourth Hospital of Hebei Medical University between January 2010 to December 2016 were recruited. Winthin the whole group,130 patients (65.3%) had distant lymph node metastases alone, 51 cases (25.6%) of solid organ metastases alone and 18 cases (9.0%) of solid organ complicated with distant lymph node metastases. Among them, 16 patients (8.0%) were treated with chemotherapy alone, 50 cases (25.1%) of radiotherapy alone, 133 cases (66.8%) of radiochemotherapy (81 patients treated with concurrent radiochemotherapy and 52 patients treated with sequential radiochemotherapy). The survival rate was calculated by Kaplan-Meier method and the difference was analyzed by log-rank test. Clinical prognosis was assessed by multivariate Cox regression model. Results The median overall survival (OS) of the entire cohort was 12.3 months (95%CI:10.6-15.4m), and the 1-, 2-, 3-and 5-year OS rates were 52.1%, 25.2%, 19.1%, and 11.5%, respectively. Multivariate analysis showed that tumor length, the number of metastatic organs, and treatment modalities were the independent prognostic factors for OS. There was no significant difference in OS between concurrent radiochemotherapy and sequential radiochemotherapy (P=0.955). The OS of patients in the radiotherapy dose of ≥6000 cGy group was significantly longer than that of their counterparts in the 4500-5039 cGy and 5040-6000 cGy groups (both P<0.001). Conclusions For stage ⅣB thoracic ESCC patients at initial diagnosis, tumor length ≤3cm, single organ metastasis, and radiochemotherapy strategy are significantly correlated with longer OS. For stage Ⅳ ESCC patients with good physical status, radiotherapy can be supplemented on the basis of systemic chemotherapy. Concurrent or sequential radiochemotherapy needs to be individualized. If patients are tolerable, radiochemotherapy is recommended to the primary tumor or non-regional metastatic lymph nodes, aiming to prolong the OS of patients.
Wang Xuefeng,Cao Feng,Jing Shaowu et al. Radiotherapy is beneficial for long-term survival of patients with stage ⅣB thoracic esophageal squamous cell carcinoma at initial diagnosis[J]. Chinese Journal of Radiation Oncology, 2021, 30(6): 543-548.
[1] Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual (eighth edition)[M]. New York:Springer, 2017:185-202. DOI:10.1007/978-3-319-40618-3. [2] Tanaka T, Fujita H, Matono S, et al. Outcomes of multimodality therapy for stage ⅠVB esophageal cancer with distant organ metastasis (M1-Org)[J]. Dis Esophagus, 2010, 23(8):646-651.DOI:10.1111/j.1442-2050.2010.01069.x. [3] Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus april 2012 edited by the Japan Esophageal Society[J]. Esophagus, 2015, 12(1):1-30.DOI:10.1007/s10388-014-0465-1. [4] Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer:Phase Ⅲ KEYNOTE-181study[J]. J Clin Oncol, 2019, 37(4 suppl):2-2. DOI:10.1093/annonc/mdz154.011. [5] Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3):a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol. 2019, 20(11):1506-1517.DOI:10.1016/S1470-2045(19)30626-6. [6] Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT):a multicentre, randomised, open-label, phase 3study[J]. Lancet Oncol. 2020, 21(6):832-842. DOI:10.1016/S1470-2045(20)30110-8. [7] Guttmann DM, Mitra N, Bekelman J, et al. Improved overall survival with aggressive primary tumor radiotherapy for patients with metastatic esophageal cancer[J]. J Thorac Oncol, 2017, 12(7):1131-1142. DOI:10.1016/j.jtho.2017.03.026. [8] 郭俊俊,高巍,王蒨,等.133例Ⅳ期食管癌的临床回顾性分析[J]. 中华放射肿瘤学杂志, 2020, 29(2):102-105. DOI:10.3760/cma.j.issn.1004-4221.2020.02.005. Guo JJ, Gao W, Wang Q, et al. Retrospective clinical analysis of 133 cases of stage IV esophageal cancer[J]. Chin J Radiat Oncol, 2020, 29(2):102-105. DOI:10.3760/cma.j.issn.1004-4221.2020.02.005. [9] Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer[J]. Ann Surg, 2020, 271(4):693-700.DOI:10.1097/SLA.0000000000002985. [10] Li C, Wang Z, Duan A, et al. Analysis on plausible factors related to the prognosis of stage ⅠV esophageal cancer[J]. Medicine, 2020, 99(12):e18529. DOI:10.1097/MD.0000000000018529. [11] Ikeda E, Kojima T, Kaneko K, et al. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage ⅠVB esophageal cancer patients with dysphagia[J]. Jpn J Clin Oncol, 2011, 41(8):964-972. DOI:10.1093/jjco/hyR088. [12] Suzuki G, Yamazaki H, Aibe N, et al. Palliative radiotherapy in the local management of stage ⅠVb esophageal cancer:factors affecting swallowing and survival[J]. Anticancer Res, 2017, 37(6):3085-3092. DOI:10.21873/anticanres.11664. [13] Moreno AC, Zhang N, Giordano S, et al. Comparative effectiveness of chemotherapy alone versus chemotherapy and radiation therapy for patients with stage ⅠV esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(2):E172-E173.DOI:10.1016/j.ijrobp.2017.06.1014. [14] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation therapy oncology group[J]. JAMA, 1999, 281(17):1623-1627.DOI:10.1001/jama.281.17.1623. [15] Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123(Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy[J]. J Clin Oncol, 2002, 20(5):1167-1174.DOI:10.1200/JCO.2002.20.5.1167. [16] Gaspar LE, Qian C, Kocha WI, et al. A phase Ⅰ/Ⅱ study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07):preliminary toxicity report[J]. Int J Radiat Oncol Biol Phys, 1997, 37(3):593-599. DOI:10.1016/0360-3016(95)97702-3. [17] Feng JF, Huang Y, Zhao Q. Tumor length in elderly patients with esophageal squamous cell carcinoma:is it a prognostic factor?[J]. Ups J Med Sci, 2013, 118(3):145-152. DOI:10.3109/03009734.2013.792887.
2021, Vol. 30 
